IMA401-101 - therapeutisch

Gynecological tumors / Breast cancer, Skin tumors, Thoracic tumors, Urogenital tumors
Breast cancer, Melanoma, Non-small cell lung cancer (NSCLC), Urothelial carcinoma of the urinary bladder (incl. renal pelvis, ureter)
Follow-Up Treatment (Metastatic Disease)
Primary objective: - To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 Secondary objectives: - To characterize the safety and tolerability of IMA401 - To evaluate initial anti-tumor activity of IMA401 - To describe the pharmacokinetics of IMA401
A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors.